Wall Street analysts expect KemPharm Inc (NASDAQ:KMPH) to report ($0.98) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for KemPharm’s earnings, with estimates ranging from ($1.18) to ($0.86). KemPharm reported earnings of ($0.44) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 122.7%. The firm is expected to issue its next earnings results on Thursday, August 9th.
According to Zacks, analysts expect that KemPharm will report full year earnings of ($4.11) per share for the current financial year, with EPS estimates ranging from ($4.41) to ($3.68). For the next year, analysts forecast that the business will post earnings of ($2.78) per share, with EPS estimates ranging from ($3.47) to ($2.10). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for KemPharm.
KemPharm (NASDAQ:KMPH) last announced its earnings results on Thursday, May 10th. The specialty pharmaceutical company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.41).
A number of equities analysts have recently weighed in on KMPH shares. ValuEngine upgraded KemPharm from a “strong sell” rating to a “sell” rating in a research note on Friday, March 9th. Zacks Investment Research upgraded KemPharm from a “hold” rating to a “buy” rating and set a $7.50 target price on the stock in a research note on Wednesday, March 21st. Oppenheimer restated a “buy” rating on shares of KemPharm in a research note on Thursday, March 22nd. Finally, Roth Capital set a $10.00 target price on KemPharm and gave the stock a “buy” rating in a research note on Monday, April 2nd. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $11.21.
Shares of NASDAQ KMPH traded down $0.10 during midday trading on Wednesday, reaching $6.40. The company’s stock had a trading volume of 60,883 shares, compared to its average volume of 129,228. KemPharm has a 12-month low of $2.45 and a 12-month high of $8.40. The company has a market capitalization of $98.18 million, a PE ratio of -2.16 and a beta of -0.19. The company has a quick ratio of 2.83, a current ratio of 2.83 and a debt-to-equity ratio of -1.13.
In other news, EVP Daniel L. Cohen acquired 7,900 shares of the company’s stock in a transaction that occurred on Tuesday, May 15th. The shares were acquired at an average price of $6.45 per share, for a total transaction of $50,955.00. Following the completion of the purchase, the executive vice president now owns 35,500 shares in the company, valued at $228,975. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 25.90% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of KMPH. Victory Capital Management Inc. lifted its stake in KemPharm by 10.9% in the first quarter. Victory Capital Management Inc. now owns 179,737 shares of the specialty pharmaceutical company’s stock valued at $1,420,000 after purchasing an additional 17,660 shares during the last quarter. ING Groep NV purchased a new position in KemPharm in the first quarter valued at approximately $1,102,000. JPMorgan Chase & Co. lifted its stake in KemPharm by 15,976.2% in the first quarter. JPMorgan Chase & Co. now owns 100,637 shares of the specialty pharmaceutical company’s stock valued at $795,000 after purchasing an additional 100,011 shares during the last quarter. Change Path LLC purchased a new position in KemPharm in the first quarter valued at approximately $479,000. Finally, Millennium Management LLC purchased a new stake in shares of KemPharm during the first quarter worth $122,000. Institutional investors and hedge funds own 36.49% of the company’s stock.
KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's lead product candidates include KP415 and KP484, which are extended release prodrugs of methylphenidate for the treatment of attention deficit hyperactivity disorder.
Get a free copy of the Zacks research report on KemPharm (KMPH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.